"&#xa0;\n&#xa0;\nIs there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified? \n&#xa0;&#xa0;\n&#xa0;\n&#xa0;\nWhat measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens? \n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nHow has antimicrobial resistance developed in the past decade? \n&#xa0;\nNo comments\n&#xa0;\nWhat are the gaps in our knowledge about antimicrobial resistance? \n&#xa0;\nNo comments \n&#xa0;What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives? \n&#xa0;\nNo comments\n&#xa0;\nWhat are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?\n&#xa0;\nNo comments \n&#xa0;\n&#xa0;\nAbout BPS \nBPS is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, toxicological and regulatory aspects. \nClinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.\n&#xa0;\nNovember 2013\n&#xa0;\n"